rss
J Med Genet 2007;44:603-605 doi:10.1136/jmg.2007.049718
  • Letters to JMG

Genetic association analysis of inositol polyphosphate phosphatase-like 1 (INPPL1, SHIP2) variants with essential hypertension

  1. Ana Carolina Braga Marçano1,
  2. Beverley Burke1,
  3. Johannie Gungadoo1,
  4. Chris Wallace1,
  5. Pamela J Kaisaki2,
  6. Peng Y Woon2,
  7. Martin Farrall3,
  8. David Clayton4,
  9. Morris Brown4,
  10. Anna Dominiczak5,
  11. John M Connell5,
  12. John Webster6,
  13. Mark Lathrop7,
  14. Mark Caulfield1,
  15. Nilesh Samani8,
  16. Dominique Gauguier2,
  17. Patricia B Munroe1
  1. 1Clinical Pharmacology and The Genome Centre, Barts and The London School of Medicine and Dentistry, London, UK
  2. 2The Wellcome Trust Centre for Human Genetics, University of Oxford, Oxford, UK
  3. 3Department of Cardiovascular Medicine, University of Oxford, Wellcome Trust Centre for Human Genetics, Oxford, UK
  4. 4Clinical Pharmacology and the Cambridge Institute of Medical Research, University of Cambridge, Addenbrooke’s Hospital, Cambridge, UK
  5. 5BHF Glasgow Cardiovascular Research Centre, Division of Cardiovascular and Medical Sciences, University of Glasgow, Western Infirmary, Glasgow, UK
  6. 6Medicine and Therapeutics, Aberdeen Royal Infirmary, Aberdeen, UK
  7. 7Centre National de Genotypage, Evry, France
  8. 8Cardiology, University of Leicester, Glenfield Hospital, Leicester, UK
  1. Correspondence to:
 Patricia B Munroe
 PhD, Clinical Pharmacology, William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Charterhouse Square, London, EC1M 6BQ; p.b.munroe{at}qmul.ac.uk
  • Received 9 February 2007
  • Accepted 6 May 2007
  • Revised 25 April 2007
  • Published Online First 8 June 2007

Abstract

Background: Inositol polyphosphate phosphatase-like 1 (INPPL1, SHIP2) is a negative regulator of insulin signalling and has previously been found to be associated with hypertension, obesity and type 2 diabetes in a cohort of families with diabetes in the UK presenting features of metabolic syndrome. In particular, a haplotype of three genetic polymorphisms (rs2276047, rs9886 and an insertion/deletion polymorphism in intron 1) was found to be strongly associated with increased susceptibility to hypertension.

Objective and methods: To assess if INPPL1 variants play a direct role in the development of essential hypertension, we genotyped the three previously associated INPPL1 polymorphisms in a cohort of 712 families with severe hypertension from the BRIGHT study transmission disequilibrium test cohort.

Results: We found no evidence of significant association between hypertension and any of the three INPPL1 polymorphisms or haplotypes (p>0.1).

Conclusion: These results suggest that INPPL1 variants may be involved in mechanisms causing hypertension in metabolic syndrome patients specifically.

Footnotes

  • Competing interests: None declared.

  • Published Online First 8 June 2007

This Article

  1. Abstract
  2. Full text
  3. PDF
  4. All Versions of this Article:
    1. jmg.2007.049718v1
    2. 44/9/603 most recent

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
 This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of JMG.
View free sample issue >>

Free archive
The full back archive is now available for JMG. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

    • Latest genetics jobs

    Latest genetics jobs

    Show me all Genetics jobs >>